However, VHL-defective ccRCC cell lines display unexpectedly variable sensitivity to HIF-2α-targeted therapies [11], which provide effective treatment for only a subset of patients [140]. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.